Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional clinical review · English · RheumaView

Raynaud phenomenon and very early systemic sclerosis

Raynaud phenomenon is common; systemic sclerosis is not. Puffy fingers, a scleroderma capillary pattern and disease-specific antibodies change the context and justify focused assessment.

Olga Goodman, MD · Evidence checked: 25 September 2026

← Topic map

Start with the phenomenon

Clarify episodic colour change, cold or emotional triggers, duration, symmetry, pain and recovery. Photographs can help when the examination is normal. Persistent pallor, severe pain, tissue loss or a non-healing lesion requires a vascular assessment rather than routine reassurance. Review medications, occupational vibration, smoking and other causes of secondary Raynaud phenomenon.

Recognize an early pattern

Examine for puffy fingers, sclerodactyly, digital pits, telangiectasia and abnormal nailfold capillaries. Integrate ANA and SSc-specific serology with the history and examination. VEDOSS is a framework for recognizing and following an at-risk clinical pattern. Its cohort progression estimates are not a personal probability calculator for every individual with Raynaud phenomenon.

The original registry studied a selected population. Referral setting, combinations of findings, missing follow-up and the definition of progression matter when discussing its results. Neither a single antibody nor isolated nonspecific capillary changes should be converted into a diagnosis without clinical context.

Make uncertainty actionable

State whether the current picture favours primary Raynaud phenomenon, a possible evolving connective-tissue disease, or established SSc. Give a reason for any planned repeat examination or investigations. New puffy fingers, ulcers, skin tightening, unexplained breathlessness or objective weakness may change the assessment before a scheduled follow-up.

Classification and diagnosis

The ACR/EULAR classification framework supports consistent research populations. A person can warrant expert assessment before reaching a classification threshold, and a score should not override a better explanation for their findings. Clinical diagnosis, research classification and risk surveillance are related but distinct tasks.

Practical endpoint

The useful output is a documented phenotype, a proportionate investigation plan and explicit triggers for re-evaluation. Repeated broad antibody panels without a clinical question can amplify noise instead of improving this plan.

Practice with a clinical case

Related professional quiz · Open demo, no registration required · EN / RU / ES / PL.

Try the open demo Browse the quiz series

Sources & further reading

  1. VEDOSS longitudinal study of progression from Raynaud phenomenon
  2. False-positive anti-Scl-70 results in a scleroderma referral-centre case series
  3. British Society for Rheumatology guideline for systemic sclerosis, 2024

Olga Goodman, MD · Rheumatology in Perspective · A RheumaView publication

Educational information, not a diagnosis or an individual treatment plan. Do not change medicines without your treating team. For an emergency, contact local emergency services.

A personal educational publication, not a clinic portal. Any private services are separate, direct-pay services; insurance is not accepted.

© 2026 Olga Goodman, MD. Attribution is required when quoting or sharing these materials.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Rheumatology